A new treatment for children and adults with a rare, inherited form of vision loss is the first gene therapy approved in the United States for a genetic disease.
Voretigene neparvovec-rzyl, marketed as Luxturna, is indicated for patients with confirmed biallelic RPE65 mutation–associated retinal dystrophy. Only patients with mutations on both copies of the RPE65 gene who have sufficient viable retinal cells should receive the therapy. It is a one-time treatment administered by subretinal injection.
Voelker R. Gene Therapy for Vision Loss. JAMA. 2018;319(5):434. doi:10.1001/jama.2017.21710
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: